BioSpace News Archive

Mereo BioPharma Group plc today announced senior management’s participation in three upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference 1x1 meetings, September 13 – 14, 2021

Amolyt Pharma and PeptiDream Inc. announced that Amolyt Pharma has exercised its option to globally license a portfolio of macrocyclic peptide growth hormone receptor antagonists under the terms of its research collaboration agreement with PeptiDream announced in December 2020.

Entasis Therapeutics Holdings Inc. announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference.

Global Blood Therapeutics, Inc. announced that on September 1, 2021, the compensation committee of GBT’s board of directors granted 20 new employees options to purchase an aggregate of 49,600 shares of the company’s common stock with a per share exercise price of $29.85 and restricted stock units for an aggregate of 79,910 shares of the company’s common stock.

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene for whom there are no effective disease modifying therapies.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the final clinical results from its Phase I clinical study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart disease.

Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (“CNS”) and oncology-related diseases. Today, Vyant Bio announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Conference.

Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company’s strategic focus on innovation in the areas of discovery, clinical development and manufacturing

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.

Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.